newest glp-1 drugs What to Make of the Coverage and Cost Landscape Decoding GLP-1 Weight Loss Medications

By enhancing autophagy and stabilizing mitochondria indirectly via AMPK and SIRT, GLP-1RAs may also act as indirect suppressors of pathological STING activation

The original development partner, Janssen Pharmaceuticals, has handed back the license for efinopegdutide to the original developer, Hanmi Pharmaceutical, but the license has been taken up by Merck to be developed as a once weekly treatment for NAFLD

IBX joined other major insurers like Kaiser Permanente, Blue Cross Blue Shield of Michigan, Mass Health, North Carolinas State Health Plan and others in restricting or dropping coverage for GLP-1 medications

Advantage : Survodutide MASH / Liver Disease# Pemvidutide : Phase 2b IMPACT trial showed 59.1% MASH resolution at 1.2 mg and 52.1% at 1.8 mg vs 19.1% placebo at 24 weeks

MIM received honoraria for speaking at meetings from AstraZeneca, Novo Nordisk, Bruno Farmaceutici, Mundipharma, and Sanofi